Purpose of this Study
We are doing this study to see if the study drugs, domvanalimab and zimberelimab, are safe and effective for treating advanced or metastatic gastroesophageal adenocarcinoma.
Who Can Participate?
Eligibility
Adults ages 18+ who are diagnosed with one of the following types of cancer:
- Esophageal adenocarcinoma (a common type of cancer of the esophagus); OR
- Gastroesophageal junction adenocarcinoma (cancer where the esophagus meets the stomach); OR
- Gastric adenocarcinoma (stomach cancer)
The cancer must not be treatable with surgery alone.
For more information about who can join this study, please contact the study team at 919-668-1861.
- Esophageal adenocarcinoma (a common type of cancer of the esophagus); OR
- Gastroesophageal junction adenocarcinoma (cancer where the esophagus meets the stomach); OR
- Gastric adenocarcinoma (stomach cancer)
The cancer must not be treatable with surgery alone.
For more information about who can join this study, please contact the study team at 919-668-1861.
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
If you choose to join this study, you will:
- Receive the study drugs, domvanalimab and zimberelimab, through an IV once every 3 or 4 weeks
- Receive standard chemotherapy every 2 weeks in addition to the study drugs (if not previously treated)
- Have blood draws
- Get CT or MRI scans every 6-to-12 weeks
- Receive the study drugs, domvanalimab and zimberelimab, through an IV once every 3 or 4 weeks
- Receive standard chemotherapy every 2 weeks in addition to the study drugs (if not previously treated)
- Have blood draws
- Get CT or MRI scans every 6-to-12 weeks
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
Yes
Study Details
Full Title
A Phase 2 Trial to Evaluate the Safety and Efficacy of Domvanalimab (AB154) and Zimberelimab (AB122) -Based Treatment Combinations in Patients with Advanced Upper Gastrointestinal Tract Malignancies
Principal Investigator
Hope
Uronis
Protocol Number
PRO00111012
NCT ID
NCT05329766
Phase
II
Enrollment Status
OPEN TO ACCRUAL